Allarity Therapeutics ALLR
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Allarity Therapeutics (ALLR)
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
Key Insights
Critical company metrics and information
Latest Closing Price
$1.06Market Cap
$4.70 MillionPrice-Earnings Ratio
-0.14Total Outstanding Shares
4.43 Million SharesTotal Employees
6Dividend
No dividendIPO Date
December 21, 2021SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQType
Common StockHeadquarters
24 school st., 2nd floor, Boston, MA, 02108Homepage
https://www.allarity.com
Historical Stock Splits
If you bought 840,000 shares of ALLR before March 27, 2023, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| September 11, 2024 | 1-for-30 (Reverse Split) |
| April 9, 2024 | 1-for-20 (Reverse Split) |
| June 29, 2023 | 1-for-40 (Reverse Split) |
| March 27, 2023 | 1-for-35 (Reverse Split) |
Cash Flow Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $575,000 |
| Net Cash Flow From Financing Activities, Continuing | $4.87 Million |
| Exchange Gains/Losses | $-195,000 |
| Net Cash Flow From Operating Activities | $-5.44 Million |
| Net Cash Flow From Operating Activities, Continuing | $-5.44 Million |
| Net Cash Flow, Continuing | $390,000 |
Income Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Income/Loss From Continuing Operations After Tax | $-11.59 Million |
| Income Tax Expense/Benefit, Deferred | $-432,000 |
| Net Income/Loss Available To Common Stockholders, Basic | $-12.15 Million |
| Income/Loss From Continuing Operations Before Tax | $-11.97 Million |
| Income Tax Expense/Benefit | $-377,000 |
Comprehensive Income
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-11.75 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $-11.75 Million |
| Comprehensive Income/Loss Attributable To Parent | $-11.75 Million |
Balance Sheet
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Current Liabilities | $7.41 Million |
| Noncurrent Assets | $12,000 |
| Equity | $12.96 Million |
| Intangible Assets | $0 |
| Equity Attributable To Noncontrolling Interest | $0 |
| Assets | $20.38 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about ALLR from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.